Next Article in Journal
Phospholipase D2 Enhances Epidermal Growth Factor-Induced Akt Activation in EL4 Lymphoma Cells
Next Article in Special Issue
EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
Previous Article in Journal
NSAIDs and Cell Proliferation in Colorectal Cancer
Previous Article in Special Issue
Aptamers for Targeted Drug Delivery
Open AccessReview

Demethylating Agents in the Treatment of Cancer

University of South Alabama, Mitchell Cancer Institute/1660 Springhill Ave., Mobile, AL 36604, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(7), 2022-2044; https://doi.org/10.3390/ph3072022
Received: 4 May 2010 / Revised: 22 June 2010 / Accepted: 29 June 2010 / Published: 2 July 2010
(This article belongs to the Special Issue Targeted Therapy)
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy. View Full-Text
Keywords: azacitidine; cancer; decitabine; epigenetics; methylation azacitidine; cancer; decitabine; epigenetics; methylation
MDPI and ACS Style

Howell, P.M., Jr.; Liu, Z.; Khong, H.T. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals 2010, 3, 2022-2044.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop